Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 박병배 | - |
dc.date.accessioned | 2021-02-17T02:23:06Z | - |
dc.date.available | 2021-02-17T02:23:06Z | - |
dc.date.issued | 2019-12 | - |
dc.identifier.citation | LEUKEMIA & LYMPHOMA, v. 60, no. 13, page. 3251-3257 | en_US |
dc.identifier.issn | 1042-8194 | - |
dc.identifier.issn | 1029-2403 | - |
dc.identifier.uri | https://www.tandfonline.com/doi/full/10.1080/10428194.2019.1622100 | - |
dc.identifier.uri | https://repository.hanyang.ac.kr/handle/20.500.11754/158533 | - |
dc.description.abstract | This trial was designed to investigate the efficacy and toxicity of bendamustine, carboplatin, and dexamethasone (BCD) for relapsed or refractory peripheral T-cell lymphomas (PTCLs), which would be expected to exhibit more promising clinical outcomes compared with bendamustine therapy alone. After treatments with BCD, eight patients exhibited a complete response (CR; 29%) and seven exhibited a partial response (PR; 25%). The overall response rate (ORR) was 54%. Five patients proceeded to ASCT and three patients finally achieved CR. The median progression-free survival (PFS) was 4.4 months (2.8-6.0, 95% CI). For a total of 85 cycles of BCD, grade 3 or 4 neutropenia, thrombocytopenia, and anemia occurred in 17.6, 38.8, and 16.5% of cycles, respectively. Only one patient experienced febrile neutropenia. BCD was a considerable salvage regimen for relapsed or refractory PTCLs with acceptable toxicity; AITL or ASCT eligible patients were more effective to BCD. ClinicalTrials.gov Identifier: NCT02424045 | en_US |
dc.language.iso | en | en_US |
dc.publisher | TAYLOR & FRANCIS LTD | en_US |
dc.subject | Lymphoma and Hodgkin disease | en_US |
dc.subject | neoplasia | en_US |
dc.subject | salvage therapy | en_US |
dc.subject | bendamustine | en_US |
dc.title | A phase II trial of bendamustine, carboplatin, and dexamethasone for refractory or relapsed peripheral T-cell lymphoma (BENCART trial) | en_US |
dc.type | Article | en_US |
dc.relation.no | 13 | - |
dc.relation.volume | 60 | - |
dc.identifier.doi | 10.1080/10428194.2019.1622100 | - |
dc.relation.page | 3251-3257 | - |
dc.relation.journal | LEUKEMIA & LYMPHOMA | - |
dc.contributor.googleauthor | Park, Byeong-Bae | - |
dc.contributor.googleauthor | Kim, Won Seog | - |
dc.contributor.googleauthor | Suh, Cheolwon | - |
dc.contributor.googleauthor | Hong, Jung Yong | - |
dc.contributor.googleauthor | Yang, Deok-Hwan | - |
dc.contributor.googleauthor | Lee, Won Sik | - |
dc.contributor.googleauthor | Do, Young Rok | - |
dc.contributor.googleauthor | Koh, Young Il | - |
dc.contributor.googleauthor | Won, Jong-Ho | - |
dc.contributor.googleauthor | Kim, Min Kyoung | - |
dc.relation.code | 2019041254 | - |
dc.sector.campus | S | - |
dc.sector.daehak | COLLEGE OF MEDICINE[S] | - |
dc.sector.department | DEPARTMENT OF MEDICINE | - |
dc.identifier.pid | bbpark | - |
dc.identifier.orcid | https://orcid.org/0000-0001-8794-2508 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.